Head-to-head comparison
OurView Health vs SnagRx
Two GLP-1 providers, one scorecard. Both are graded on the same six Desk Score dimensions — here is how they stack up, and which one fits you.
Desk Score
OurView (OurView Health) is a 100% online multi-vertical telehealth service with an Our View Savings Club membership offering pharmacy-direct pricing on U.S.-compounded medications.
From $75/mo (lowest dose rung) sema · From $135/mo (lowest dose rung) tirz · Verified August 2026
Marked down on: A comparison table on the site quotes $90 'without membership' against $75 'with membership' while the product cards say 'No membership' and the cart charges $75 without one — the provider contradicts itself on whether a membership exists
Desk Score
SnagRx is a cash-pay GLP-1 telehealth service from Modern Metabolic Medicine, Inc.
$69/mo (promo rate) sema · $119/mo (promo rate) tirz · Verified August 2026
Marked down on: The "Was $299/$399" anchor has not been charged in any of our three checks, and the promotional rate itself has now moved twice — $99/$149 on 2026-06-19, still $99/$149 on 2026-08-11, and $69/$119 on 2026-08-29, always with the same anchor and the same expiring countdown. A rate that falls twice in ten weeks is not "locked-in flat pricing for life"
SnagRx takes this head-to-head with the higher Desk Score, 77/100 (C+) against 61/100 (C) for OurView Health. OurView Health still holds its ground where its strengths line up with yours.
Desk Score, dimension by dimension
Same six measured dimensions for both. The red flag marks the stronger side. See the methodology.
OurView Health
61/100
C
SnagRx
77/100
C+
Price transparency
State access
Molecule range
Onboarding speed
Support responsiveness
Licensing & trust
The spec sheet
| Field | OurView Health | SnagRx |
|---|---|---|
| Semaglutide | From $75/molowest dose rung$75/mo (starting dose, compounded) | $69/mopromo rate$69/mo (Summer Start promotional rate, flat at every dose, compounded) |
| Tirzepatide | From $135/molowest dose rung$135/mo (starting dose, compounded) | $119/mopromo rate$119/mo (Summer Start promotional rate, flat at every dose, compounded) |
| Coverage | Not listed on OurView Health's site (checked August 2026) | All 50 states plus Washington D.C. (per Terms) |
| Brand-name | Compounded only | Compounded only |
| Oral option | Injectable only | Injectable only |
| Best for | Budget shoppers wanting low-cost compounded GLP-1 via a membership savings model. | Compounded semaglutide and tirzepatide at a flat lifetime price. |
| Desk Score | 61/100C | 77/100C+ |
The verdict
Desk pick — SnagRxSnagRx takes this head-to-head with the higher Desk Score, 77/100 (C+) against 61/100 (C) for OurView Health. OurView Health still holds its ground where its strengths line up with yours.
Choose OurView Health if…
Budget shoppers wanting low-cost compounded GLP-1 via a membership savings model.
From $75/mo (lowest dose rung) sema · From $135/mo (lowest dose rung) tirz
Choose SnagRx if…
Compounded semaglutide and tirzepatide at a flat lifetime price.
$69/mo (promo rate) sema · $119/mo (promo rate) tirz · All 50 states plus Washington D.C. (per Terms)
Assume any provider we list may compensate us — we may earn a referral commission at no extra cost to you, and what we write about a provider reads the same either way. Read full breakdowns: OurView Health · SnagRx.
Also here
CoreAge Rx leads the whole ranking at 94/100
Whichever of these two you lean toward, our #1-rated provider outscores them both. One price at every dose, both molecules, all 50 states. The $99 and $149 figures are 12-month plans paid up front, not a monthly bill.
More head-to-heads
- CoreAge Rx vs OurView Health
- CoreAge Rx vs SnagRx
- OurView Health vs yourEra
- SnagRx vs Tyde Wellness
- OurView Health vs Sunlight
- SnagRx vs yourEra
Or see the full comparison hub and the complete ranking.
Pricing and verification reflect each provider's public disclosures at last scoring; the Desk Score is our editorial judgment per the methodology. Prices change — confirm on each provider's own site. Not medical advice; see our disclosure.